Skip to content
Home/Companies/Biotech/R1 Therapeutics

R1 Therapeutics

Biotech·US·Active·New
Entry
2026
Hold
New
Status
Active

Who owns R1 Therapeutics?

R1 Therapeutics is an American Biotech company, currently owned by Abingworth since 2026.

Hand-verified · updated 2026-07-08

Open JSON · CC-BY
Abingworth
Investor
Abingworth
Abingworth Bioventures IX · 2023 · VC

Key facts

HQUS
SectorBiotech
StatusActive

More from Abingworth Bioventures IX

Other portfolio companies in the same fund.

cAMPfield
Active
BiotechUS· 2026
Addition Therapeutics
Addition Therapeutics
Active
BiotechUS· 2025

More Abingworth portfolio companies

From the same investor, across funds.

Verona Pharma
Verona Pharma
Exited 2025
BiotechUK
to Merck & Co.
Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
AdvanCell
Active
BiotechAustralia· 2025
Antares Therapeutics
Active
BiotechUS· 2025
Solve Therapeutics
Active
BiotechUS· 2025
Timberlyne Therapeutics
Active
BiotechUS· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns R1 Therapeutics?

R1 Therapeutics is currently owned by Abingworth, through Abingworth Bioventures IX, since 2026.

When did Abingworth acquire R1 Therapeutics?

Abingworth acquired R1 Therapeutics in 2026.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue